
David Sebag: Delighted our letter about the PROSPECT rectal cancer trial
Quoting David Sebag-Montefiore, Director at Leeds Cancer Research Centre, on X/Twitter:
“Delighted our letter about the PROSPECT rectal cancer trial, with Andres Cervantes and Claus Rodel is published in The New England Journal of Medicine. We highlight important considerations in the trial findings from a global perspective and caution about its interpretation.
We strongly caution against the use of FOLFOX alone applied to the whole PROSPECT trial population. Also, FOLFOX and CRT represent significant over-treatment of a substantial proportion of the trial population (38% T3N0 disease with tumour >3mm from the mesolectal fascia).
The media description that FOLFOX allows patients to avoid the brutal side effects of radiotherapy is not balanced and misleading. The majority of late toxicity is due to radical surgery and precise modern RT reduces the additional impact of RT.”
For more information click here.
Source: David Sebag/Twitter.
-
Dec 8, 2023, 17:10 | OpinionAaron Goodman: Let’s stop giving many cured young patients neuropathy
-
Dec 8, 2023, 16:29 | BlogBecome a SIOP member today or renew for 2024 membership year - SIOP
-
Dec 8, 2023, 15:51 | BlogSharon Kapambwe: Standing on the shoulders of giants- Professor Lynnette Denny
-
Dec 8, 2023, 12:47 | InsightTalha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 9, 2023, 04:44President Biden: It's good for the millions of Americans who can't afford their medications
-
Dec 8, 2023, 17:40Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
-
Dec 8, 2023, 17:32Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
-
Dec 8, 2023, 12:47Talha Badar: A few selected ALL abstracts to watch for at ASH23
-
Dec 8, 2023, 12:40Amar Kelkar: We hope putting out independent cost-effectiveness analyses like this will encourage others to join
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 2, 2023, 16:50Mara Antonoff: When your famous friends come back to visit their humble beginnings
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Nov 26, 2023, 17:58Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
-
Dec 7, 2023, 18:30Dinesh Pendharkar is appointed as an Adjunct Professor at Roswell Park Comprehensive Cancer Center
-
Dec 7, 2023, 04:37Karun Neupane: Dreams do come true. I am going to Moffitt Cancer Center to become a hematologist/oncologist!
-
Dec 6, 2023, 16:21Sandra L. Wong has been appointed the next Dean of Emory University School of Medicine and chief academic officer for Emory Healthcare - Emory School of Medicine